XML 22 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Cash flows from operating activities:    
Net income $ 7,919 $ 6,183
Depreciation and amortization 2,215 1,844
Deferred income taxes (258) (414)
Stock-based compensation 464 383
Impairment of intangible 350  
Change in assets and liabilities, net of acquisitions    
Accounts receivable, net 493 (931)
Inventories, net 1,276 (72)
Prepaid expenses and other 38 180
Accounts payable, trade (150) (1)
Accrued liabilities and taxes payable 142 1,696
Net cash from operating activities 12,489 8,868
Cash flows from investing activities:    
Business acquisitions and intangibles (737) (17,973)
Capital expenditures (683) (2,645)
Net cash (used) by investing activities (1,420) (20,618)
Cash flow from financing activities:    
Proceeds from debt   7,000
Payments on debt (6,500) (778)
Dividends paid (1,645) (1,488)
Proceeds from stock options exercised 813 196
Treasury stock purchases (92) (105)
Net cash (used) provided by financing activities (7,424) 4,825
Net increase (decrease) in cash and cash equivalents 3,645 (6,925)
Cash and cash equivalents at beginning of year 3,546 10,471
Cash and cash equivalents at end of year 7,191 3,546
Cash paid during the year for:    
Income taxes 4,457 3,528
Cash paid for interest 176 141
Supplemental disclosure of non-cash activity (Dollars in thousands):    
Holdback amount from acquisition of the assets of Apex Laboratories 600  
Settlement of acquisition dues of Apex Laboratories, amount paid 562  
Settlement of acquisition dues of Apex Laboratories, return of accounts receivable 38  
The Company issued employee loans for the purchase of common stock during the years ended March 31, 2012 and 2011, respectively 396 437
Loans outstanding retired $ 437